



QIAreach QuantiFERON-TB for the diagnosis of *Mycobacterium tuberculosis* infection

Francesca Saluzzo 📵 1,2, Paola Mantegani 1,2, Valeria Poletti de Chaurand 📵 1 and Daniela Maria Cirillo 📵 1

¹Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. ²These authors contributed equally to this work.

Corresponding author: Daniela Maria Cirillo (cirillo.daniela@hsr.it)



Shareable abstract (@ERSpublications)

QIAreach QFT demonstrated a good performance in diagnosing TB infection. This tool may offer technical and operational benefits over more complex IGRA ELISA-based assays, granting timely TB diagnosis in decentralised settings with limited infrastructure. https://bit.ly/3n6Dxll

Cite this article as: Saluzzo F, Mantegani P, Poletti de Chaurand V, *et al.* QIAreach QuantiFERON-TB for the diagnosis of *Mycobacterium tuberculosis* infection. *Eur Respir J* 2022; 59: 2102563 [DOI: 10.1183/13993003.02563-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

This article has an editorial commentary: https://doi.org/10.1183/13993003.00149-2022

Received: 24 Sept 2021 Accepted: 12 Oct 2021 To the Editor:

Timely diagnosis and treatment to prevent tuberculosis (TB) transmission and the consequent replenishment of the TB infection reservoir are essential for the control and elimination of TB worldwide [1], ultimately contributing the World Health Organization (WHO)'s End TB goals [2].



